Drugs / AV-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04737486 | Dec 2020 → Mar 2021 | COVID-19, acute respiratory distress syndrome | Vasomune Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07234890 | Dec 2025 → Dec 2027 expected | — | London Health Sciences Centre Research Institute | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05123755 Comparator | Dec 2021 → May 2026 overdue | acute respiratory distress syndrome, viral pneumonia | Vasomune Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-03-05 | AnGes, Inc. | Regulatory 共同開発品Tie2受容体アゴニスト(AV-001)の重度熱傷患者の蘇生治療を対象とした臨床試験許可取得のお知らせ anges.co.jp ↗ |
| 2024-05-29 | AnGes, Inc. | Regulatory 共同開発品Tie２受容体アゴニスト(AV-001)が米国 FDAよりファスト・トラック指定を取得 anges.co.jp ↗ |
| 2023-11-15 | AnGes, Inc. | Results 当社の共同開発品Tie2受容体アゴニスト化合物「AV-001」第II相臨床試験の評価に関するお知らせ anges.co.jp ↗ |
| 2021-03-25 | Vasomune Therapeutics, Inc. | Results Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy vasomune.com ↗ |
| 2021-03-25 | AnGes, Inc. | Results アンジェスが共同開発するCOVID-19治療薬AV-001：第1相臨床試験で安全性と忍容性を確認し良好な結果を発表 ～FDAと協議の上、前期第2相臨床試験を開始予定～ anges.co.jp ↗ |
| 2020-11-12 | Vasomune Therapeutics, Inc. | Regulatory Vasomune Announces FDA Allowance of IND Application for AV-001 for the Treatment of Hospitalized Patients with COVID-19 vasomune.com ↗ |
| 2017-10-18 | ExpreS2ion Biotechnologies | Results ExpreS2ions nya joint venture-bolag AdaptVac uppnår Proof-of-concept i djurmodell för banbrytande bröstcancervaccin expres2ionbio.com ↗
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) meddelar idag att joint venture-bolaget AdaptVac ApS (“AdaptVac”) har uppnått Proof-of-concept i avancerade djurmodeller (POCA) för AV-001, sin nya vaccinbehandling mot bröstcancertumörer. |
| 2017-10-18 | ExpreS2ion Biotechnologies | Results ExpreS2ion’s new joint venture, AdaptVac, reaches proof of concept in animals for breakthrough breast cancer vaccine treatment expres2ionbio.com ↗
Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture, AdaptVac ApS (“AdaptVac”), has reached proof of concept in advanced animal models (POCA) for AV-001, its novel vaccine treatment against breast cancer tumours. |
All press releases naming this drug 21 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AV-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05123755 ↗ |
| Known as | mpaBr | “AV-001 (mpaBr) Cl for Injection 2.5 mg/mL” NCT04737486 ↗ |
| Action | Activate | “shown to activate the Tie2 receptor tyrosine kinase” NCT05123755 ↗ |
| Route | Intravenous | “by intravenous bolus injection” NCT04737486 ↗ |